Evidence map›Paper›PMID 33852110›Full record

ReviewHeart failure reviews2022

Biomarkers for the diagnosis and management of heart failure.

Vincenzo Castiglione, Alberto Aimo, Giuseppe Vergaro, Luigi Saccaro, Claudio Passino, Michele Emdin

2 registry-linked trialsOpen access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Heart failure reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 275 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
275citing papers in PubMed, 9 pooled it
46.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06158711 unknown statusnot on this mapstarted 2023, after this paper: background citation

A Retrospective Study of the Effect of Different Drugs Co-administration in the Treatment of Heart Failure

TypeobservationalSponsorQianfoshan HospitalRan2023 to 2024Enrolled702ConditionsHeart Failure
NCT07530029 recruitingnot on this mapstarted 2026, after this paper: background citation

Multimodal Approach to Sarcopenia and Its Prognostic Impact in Older Patients Hospitalized for Acute Heart Failure (MUSICA Study).

TypeobservationalSponsorFundacion para la Investigacion Biomedica del Hospital Universitario Ramon y CajalRan2026 to 2027Enrolled110ConditionsAcute Heart Failure (AHF), Sarcopenia, Heart Failure
3 · Its place in the literature

Who cites it

275 citing papers in PubMed, 9 syntheses or guidelines pooled it, 463 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Incident heart failure in patients with screening-detected atrial fibrillation: a post hoc analysis of the STROKESTOP and STROKESTOP II studies.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Trial
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

215 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Vincenzo CastiglioneInstitute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy.
Alberto AimoInstitute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy. albertoaimo@libero.it.ORCID 0000-0001-9129-9519
Giuseppe VergaroInstitute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy.
Luigi SaccaroInstitute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy.
Claudio PassinoInstitute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy.
Michele EmdinInstitute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy.
Scuola Superiore Sant'Anna · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure (HF) is a significant cause of morbidity and mortality worldwide. Circulating biomarkers reflecting pathophysiological pathways involved in HF development and progression may assist clinicians in early diagnosis and management of HF patients. Natriuretic peptides (NPs) are cardioprotective hormones released by cardiomyocytes in response to pressure or volume overload. The roles of B-type NP (BNP) and N-terminal pro-B-type NP (NT-proBNP) for diagnosis and risk stratification in HF have been extensively demonstrated, and these biomarkers are emerging tools for population screening and as guides to the start of treatment in subclinical HF. On the contrary, conflicting evidence exists on the role of NPs as a guide to HF therapy. Among the other biomarkers, high-sensitivity troponins and soluble suppression of tumorigenesis-2 are the most promising biomarkers for risk stratification, with independent value to NPs. Other biomarkers evaluated as predictors of adverse outcome are galectin-3, growth differentiation factor 15, mid-regional pro-adrenomedullin, and makers of renal dysfunction. Multi-marker scores and genomic, transcriptomic, proteomic, and metabolomic analyses could further refine HF management.

Indexed as

Heart FailureProteomicsBiomarkersHumansNatriuretic Peptide, BrainNatriuretic PeptidesPeptide FragmentsPrognosisBiomarkersNatriuretic Peptide, BrainNatriuretic PeptidesPeptide FragmentsBiomarkersHeart failureInflammationNatriuretic peptidesSST2Troponin

Identifiers

PMID33852110
PMCPMC8898236
OpenAlexW3153950084

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.